MicroRNAs: Potential biomarkers in cancer
- PMID: 23105877
- PMCID: PMC3453005
- DOI: 10.1007/s12291-010-0008-z
MicroRNAs: Potential biomarkers in cancer
Abstract
microRNAs (miRNAs) are evolutionarily conserved small noncoding RNAs, also known as micromanagers of gene expression. Polymorphisms in the miRNA pathway (miR-polymorphisms) are emerging as powerful tools to study the biology of a disease and have the potential to be used in disease prognosis and diagnosis. Advancements in the miRNA field also indicate a clear involvement of deregulated miRNA gene signatures in cancers, and several polymorphisms in pre-miRNA, miRNA binding sites or targets have been found to be associated with various cancers. The miRNA polymorphisms have also been reported to influence tumor aggressiveness as well as survival of cancer patients. miRNAs have a revolutionary impact on cancer research over recent years. They emerge as important players in tumorigenesis, leading to a paradigm shift in oncology. The extensive and comprehensive use of miRNA microarrays has enabled the identification of a number of miRNAs as potential biomarkers for cancer. Many miRNAs have been identified to act as oncogenes, tumor suppressors, or even modulators of cancer stem cells and metastasis. Some studies not only reported the identified miRNA biomarkers, but also deciphered their target genes and the underlying mechanisms. The rapid discovery of many miRNA targets and their relevant pathways has contributed to the development of miRNA-based therapeutics.
Keywords: Biomarker; Cancer; Epigenetic; Micro RNA; Polymorphism.
Similar articles
-
MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy.Int J Biochem Cell Biol. 2010 Aug;42(8):1273-81. doi: 10.1016/j.biocel.2009.12.014. Epub 2009 Dec 22. Int J Biochem Cell Biol. 2010. PMID: 20026422 Review.
-
MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine.Pharmacogenomics. 2009 Mar;10(3):399-416. doi: 10.2217/14622416.10.3.399. Pharmacogenomics. 2009. PMID: 19290790 Free PMC article. Review.
-
Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets.PLoS One. 2010 Sep 30;5(9):e13067. doi: 10.1371/journal.pone.0013067. PLoS One. 2010. PMID: 20927335 Free PMC article.
-
Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers.Int J Mol Sci. 2021 Jul 2;22(13):7156. doi: 10.3390/ijms22137156. Int J Mol Sci. 2021. PMID: 34281210 Free PMC article. Review.
-
The Emerging Role of MitomiRs in the Pathophysiology of Human Disease.Adv Exp Med Biol. 2015;888:123-54. doi: 10.1007/978-3-319-22671-2_8. Adv Exp Med Biol. 2015. PMID: 26663182
Cited by
-
Circulating miRNA as potential biomarkers for diabetes mellitus type 2: should we focus on searching for sex differences?J Appl Genet. 2022 May;63(2):293-303. doi: 10.1007/s13353-021-00678-5. Epub 2022 Jan 5. J Appl Genet. 2022. PMID: 34984663 Free PMC article. Review.
-
Role of MicroRNAs in Hepatocellular Carcinoma.Hepat Mon. 2014 Aug 1;14(8):e18672. doi: 10.5812/hepatmon.18672. eCollection 2014 Aug. Hepat Mon. 2014. PMID: 25337143 Free PMC article. Review.
-
Nanoparticles targeting HLA-G for gene therapy in cancer.Med Oncol. 2012 Jun;29(2):1384-90. doi: 10.1007/s12032-011-9942-8. Epub 2011 Apr 17. Med Oncol. 2012. PMID: 21499927 Review.
-
Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival.Cancer Genomics Proteomics. 2011 Jul-Aug;8(4):173-83. Cancer Genomics Proteomics. 2011. PMID: 21737610 Free PMC article.
-
Apoptosis induction in acute promyelocytic leukemia cells through upregulation of CEBPα by miR-182 blockage.Mol Biol Res Commun. 2018 Mar;7(1):25-33. doi: 10.22099/mbrc.2018.27625.1297. Mol Biol Res Commun. 2018. PMID: 29911120 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources